 |
|
|
 |
Event Co-Chairs
Paul Jacobs, Ph.D. |
Christine Cote, M.D. |
Paul Jacobs, Ph.D.
Chief Executive Officer, QUALCOMM
Paul Jacobs, Ph.D., is chief executive offi cer of QUALCOMM Incorporated and is
also a member of the Company's board of directors. Dr. Jacobs has been the primary
driver of QUALCOMM's focus on enabling wireless data services, which make the cell
phone a tool not only for voice communications, but also the most personal device for
entertainment, computing and information access.
Following completion of his Ph.D. in 1989, and a year as a post-doctoral researcher
at a French government lab in Toulouse, Dr. Jacobs joined the company full-time
in 1990, as a development engineer leading the cell phone digital signal processor
software team. His early work focused on the initial variable-rate 8 kbps speech codec
for CDMA. Following this effort, Dr. Jacobs spearheaded the wireline-quality 13 kpbs
speech codec effort, which became CDMAs initial differentiating consumer feature. The
core engineering team involved in this effort would later be integral to the development
of QUALCOMM's LaunchpadT suite of multimedia functions that ship as software
with every QUALCOMM chipset. Known as an innovative leader of a broad range of
technical teams within QUALCOMM, Dr. Jacobs has also been granted more than 25
patents for his inventions in the area of wireless technology.
In 1995, he became vice president and general manager of the combined handset
and integrated circuit division, which was subsequently divided into QUALCOMM
Consumer Products (QCP) and QUALCOMM CDMA Technologies, respectively. He was
named senior vice president of the Company in 1996 and president of QCP in 1997;
he was named executive vice president of QUALCOMM in 2000 and group president
of QWI in 2001. QCP developed and manufactured the wireless industry's fi rst CDMA
digital handsets, supporting the rapid global deployment of cdmaOne in the 1990s.
Under Dr. Jacobs, that business became the number two CDMA handset supplier in
the U.S. prior to its sale to Kyocera Wireless in 2000, with revenues of more than $1.4
billion in QUALCOMM's Fiscal 1999. At QCP, Dr. Jacobs gained extensive operational
experience, helped launch numerous CDMA systems and cultivated important
executive relationships at top network operators and manufacturers globally.
Other, important developments which began under Dr. Jacobs in QCP include the
fi rst Palm OS®-based smartphone (now a rapidly growing category of mobile devices,
with third-party operating systems, offered by numerous manufacturers). He started
QUALCOMM's initiative to include global positioning system (GPS) capabilities in cell
phones. This led to the acquisition of SnapTrackT and QUALCOMM's development
of gpsOneT, and drove the development of a uniform set of application programming
interfaces (API), to simplify the process of putting software on handsets. Dr. Jacobs
expanded this latter idea into the overall concept for the BREW® system. The system
included dynamic downloading of applications to cellphones, with checks for digital
signatures on the applications, to ensure the integrity of the content, and the business
ecosystem that enables BREW developers to engage operators globally and receive
payment for their applications. The BREW solution is now deployed by more than 40
operators around the world.
back to top »
 Christine Cote, M.D.
Corporate Vice President, Corporate Office of Science & Technology,
Johnson & Johnson
Dr. Cote joined the Corporate Office of Science & Technology in October 2004 as Vice President, Science & Technology. She began her career with Johnson & Johnson in 1997 as Vice President of Global Development for Johnson & Johnson Pharmaceutical Research and Development. In this role, Christine served as Global Franchise Leader for EPREX®/PROCRIT®.
Christine served as Chief Scientific Officer of Janssen Medical Affairs, L.L.C. joining Janssen in 2001 to lead Janssen Medical Affairs. In this role, she led teams of clinical professionals in the areas of CNS (both Psychiatry and Neurology), Pain, GI, Outcomes Research, Medical Informatics, Customer Contact Center, Medical Information, Professional Education, Regulatory Compliance, and Regional Medical Science Liaisons as well as taking a leadership role in J&J’s Global Medical Affairs Council.
Prior to joining Johnson & Johnson, Christine served in several pharmaceutical industry positions internationally with ICI/Zeneca Pharmaceuticals over a 12-year period. These included leadership roles within Clinical Research, Regulatory, Medical Affairs and Marketing. In addition, she has had diverse experiences, serving as a Research Scientist with the Medical Research Council in the UK, as well as directing a large Family Practice group in Canada.
Christine received her BSc (with Honors) in Physiology from Manchester University in England. She subsequently received her Doctorate in Medicine graduating with Honors from the University of Toronto during her 15-year residence in Canada.
back to top »
|
|
